Pathios Therapeutics is developing PTT-4256, a selective GPR65 inhibitor that targets the acidic tumor microenvironment to reverse immune cell dysfunction in solid tumors. This approach aims to enhance the efficacy of cancer immunotherapy by restoring the anti-tumorigenic activity of immune cells affected by low pH conditions.
Funding
$62.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMFounders
Product
Problem
Solid tumors create an acidic microenvironment that impairs the function of immune cells, limiting the effectiveness of cancer immunotherapies. This acidic environment disarms the anti-cancer immune response, preventing immune-mediated killing of cancer cells.
Solution
Pathios Therapeutics is developing PTT-4256, a selective, orally bioavailable GPR65 inhibitor, to address the immunosuppressive effects of the acidic tumor microenvironment. GPR65, an acid-sensing G protein-coupled receptor expressed on immune cells, drives the immunosuppressive phenotype within the tumor microenvironment. By inhibiting GPR65, PTT-4256 aims to reverse immune cell dysfunction, restore anti-tumorigenic activity, and enhance the efficacy of existing cancer immunotherapies across a range of solid tumor types. The company has initiated a Phase 1/2 clinical trial to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of PTT-4256 monotherapy.
Target Audience
The primary target audience includes patients with advanced solid tumors and the clinicians treating them, particularly those who are not responding to current immunotherapies.
Features
- Orally bioavailable, highly potent, and selective small molecule GPR65 inhibitor
- Designed to reverse the immunosuppressive effects of acidic pH in macrophages and other immune cells
- Aims to activate anti-tumorigenic pathways in the tumor microenvironment
- Demonstrated monotherapy anti-tumor activity in preclinical studies
- Currently in Phase 1/2 clinical trials (RAISIC-1) evaluating safety, tolerability, and preliminary efficacy
- Human genetic analysis demonstrates that reductions in GPR65 function are associated with significantly improved survival across a range of solid tumour types